NEW YORK (GenomeWeb News) – Aragen Bioscience has licensed the rights to use Cevec Pharmaceuticals' CAP-T protein production technology in its custom recombinant cell line offerings, CEVEC said today.
The license gives Aragen the rights to offer its research clients custom recombinant human cell lines that express biotherapeutic proteins and antibodies using the Cevec technology, which is based on CAP cells, a cell line used for stable protein production.
These non-tumor origin cell lines exhibit high protein expression, have been adapted to serum-free suspension culture, and they include human-like post-translational modifications.
"We believe that human cells will be a superior production system for a variety of complex proteins," Aragen Bioscience CEO Rick Srigley said in a statement. "Cevec's technology is a valuable addition to our existing expression portfolio and will enable our customers to pursue new directions for proteins that were difficult in the past or did not show satisfactory post-translational modifications."
Financial terms of the agreement were not released.